Andrew R. Zolopa

Best Publications

• Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

  David R. Bangsberg;Frederick M. Hecht;Edwin D. Charlebois;Andrew R. Zolopa

  1350
  Citations

• Non-adherence to highly active antiretroviral therapy predicts progression to Aids

  David R. Bangsberg;Sharon Perry;Edwin D. Charlebois;Richard A. Clark

  1227
  Citations

• Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

  Andrew R. Zolopa;Janet Andersen;Lauren Komarow;Ian Sanne

  712
  Citations

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

  Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  593
  Citations

• The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan

  Victor DeGruttola;Lynn Dix;Richard D'Aquila;Dan Holder

  449
  Citations

• High levels of adherence do not prevent accumulation of HIV drug resistance mutations.

  David R Bangsberg;Edwin D Charlebois;Robert M Grant;Mark Holodniy

  356
  Citations

• Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.

  Phyllis C Tien;Andy I Choi;Andrew R Zolopa;Constance Benson

  349
  Citations

• Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

  Roy M. Gulick;Zhaohui Su;Charles Flexner;Michael D. Hughes

  316
  Citations

• Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

  Thomas D. Wu;Celia A. Schiffer;Matthew J. Gonzales;Jonathan Taylor

  296
  Citations

• HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample.

  Andrew R. Zolopa;Judith A. Hahn;Robert Gorter;Jeanne Miranda

  284
  Citations

• HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

  Andrew R. Zolopa;Robert W. Shafer;Ann Warford;Jose G. Montoya

  274
  Citations

• Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study

  Paul E. Sax;Andrew Zolopa;Indira Brar;Richard Elion

  270
  Citations

• HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance

  Soo-Yon Rhee;Jonathan Taylor;W. Jeffrey Fessel;David Kaufman

  267
  Citations

• A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.

  Andrew Zolopa;Paul E. Sax;Edwin Dejesus;Anthony Mills

  205
  Citations

• Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

  Philip M. Grant;Lauren Komarow;Janet Andersen;Irini Sereti

  195
  Citations

• Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug-Resistant HIV-1 Infection

  Thomas B. Campbell;Nancy S. Shulman;Steven C. Johnson;Andrew R. Zolopa

  169
  Citations

• Evidence for Genetic Regulation of Susceptibility to Toxoplasmic Encephalitis in AIDS Patients

  Yasuhiro Suzuki;Sin-Yew Wong;F. Carl Grumet;Jeffrey Fessel

  165
  Citations

• Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

  Martin Markowitz;Andrew Zolopa;Kathleen Squires;Peter Ruane

  162
  Citations

• HIV-1 Protease and Reverse-Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance

  Soo-Yon Rhee;W. Jeffrey Fessel;Andrew R. Zolopa;Leo Hurley

  155
  Citations

• Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors

  Matthew J. Gonzales;Thomas D. Wu;Jonathan Taylor;Ilana Belitskaya

  151
  Citations